#1 Clinical Trials Search in Europe

Mirikizumab

Mirikizumab is an investigational drug being studied in clinical trials for the treatment of inflammatory bowel diseases, particularly ulcerative colitis and Crohn’s disease. These trials aim to evaluate the efficacy, safety, and long-term effects of mirikizumab in both adult and pediatric patients with moderate to severe forms of these conditions. The studies explore various dosing methods, formulations, and treatment durations to determine the optimal use of mirikizumab in managing these chronic inflammatory disorders.

Table of Contents

What is Mirikizumab?

Mirikizumab, also known by its research code LY3074828, is an investigational drug being developed for the treatment of inflammatory bowel diseases (IBD)[1]. It is a type of medication called a biologic, which means it is made from living organisms and designed to target specific parts of the immune system[2].

What Conditions Does Mirikizumab Treat?

Mirikizumab is being studied primarily for the treatment of two main types of inflammatory bowel diseases:

  • Ulcerative Colitis (UC): A condition that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum[1].
  • Crohn’s Disease (CD): A type of IBD that can affect any part of the digestive tract, from the mouth to the anus[2].

These conditions can cause symptoms such as abdominal pain, diarrhea, rectal bleeding, and fatigue. Mirikizumab is being investigated as a potential treatment option for patients with moderate to severe forms of these diseases[3].

How Does Mirikizumab Work?

Mirikizumab is a type of drug called a monoclonal antibody. It works by targeting a specific protein in the body called interleukin-23 (IL-23). IL-23 is believed to play a key role in causing inflammation in the intestines of people with UC and CD. By blocking IL-23, mirikizumab aims to reduce inflammation and improve symptoms of these conditions[4].

How is Mirikizumab Administered?

Mirikizumab can be administered in two main ways:

  • Intravenously (IV): This means the drug is given directly into a vein through a needle or catheter[5].
  • Subcutaneously (SC): This involves injecting the medication just under the skin[6].

The method of administration and dosage may vary depending on factors such as the patient’s age, weight, and the specific condition being treated. In some clinical trials, patients start with IV doses and then switch to SC injections for maintenance therapy[5].

Mirikizumab in Clinical Trials

Mirikizumab is currently being studied in several clinical trials for both adults and children with UC and CD. These trials are designed to evaluate the drug’s effectiveness, safety, and how well it’s tolerated by patients. Some key aspects of these trials include:

  • Long-term studies: Some trials are looking at the long-term effects of mirikizumab, lasting up to 3 years or more[4].
  • Pediatric studies: Researchers are investigating the use of mirikizumab in children and teenagers with UC and CD[5].
  • Different dosing regimens: Various doses and schedules of mirikizumab are being tested to find the most effective and safe approach[3].

Efficacy of Mirikizumab

Clinical trials are measuring the effectiveness of mirikizumab in several ways:

  • Clinical remission: This means that symptoms of the disease have significantly improved or disappeared[4].
  • Endoscopic improvement: This involves checking the inside of the intestines with a camera to see if inflammation has decreased[5].
  • Histologic remission: This means that when tissue samples are examined under a microscope, there are fewer signs of inflammation[4].
  • Quality of life improvements: Researchers are looking at how mirikizumab affects patients’ overall well-being and daily activities[1].

Early results from these trials suggest that mirikizumab may be effective in helping some patients achieve remission and improve their symptoms, but more research is needed to fully understand its benefits[4].

Safety and Side Effects

As with any medication, mirikizumab may cause side effects. Clinical trials are carefully monitoring patients for any adverse reactions. Common side effects observed in studies include:

  • Injection site reactions (redness, swelling, or pain at the injection site)
  • Upper respiratory tract infections
  • Headache
  • Fatigue

More serious side effects are also being monitored, including the risk of infections. It’s important to note that the full safety profile of mirikizumab is still being established through ongoing research[4].

Ongoing Research and Future Prospects

Research on mirikizumab is ongoing, with several studies still in progress. Some areas of current investigation include:

  • Long-term effectiveness and safety: Researchers are studying how well mirikizumab works and how safe it is when used for extended periods[4].
  • Use in different patient populations: Studies are looking at the drug’s effects in various age groups and in patients with different severities of UC and CD[7].
  • Comparison with other treatments: Some trials may compare mirikizumab to existing therapies for IBD to see how it measures up[8].
  • Bioequivalence studies: These studies compare different formulations of mirikizumab to ensure they have the same effect in the body[6].

If the results of these studies continue to be promising, mirikizumab could potentially become a new treatment option for patients with UC and CD in the future. However, it’s important to remember that the drug is still investigational and not yet approved for general use outside of clinical trials[3].

Aspect Details
Drug Name Mirikizumab (LY3074828)
Conditions Studied Ulcerative Colitis, Crohn’s Disease
Patient Population Adults and Pediatrics
Administration Methods Intravenous (IV), Subcutaneous (SC)
Primary Outcomes Clinical Remission, Endoscopic Response, Pharmacokinetics
Secondary Outcomes Quality of Life, Histologic Remission, Corticosteroid-free Remission
Study Durations Ranging from 12 weeks to 3 years
Formulations Tested Pre-filled Syringes, Autoinjectors
Safety Assessments Adverse Events, Tolerability
Long-term Evaluations Efficacy, Safety, and Quality of Life Measures

FAQ

  • What is mirikizumab? Mirikizumab (also known as LY3074828) is an investigational drug being studied for the treatment of inflammatory bowel diseases, particularly ulcerative colitis and Crohn's disease. It is administered either intravenously (IV) or subcutaneously (SC).
  • What conditions is mirikizumab being studied for? Mirikizumab is primarily being studied for moderately to severely active ulcerative colitis and Crohn's disease in both adult and pediatric patients.
  • How is mirikizumab administered in clinical trials? In clinical trials, mirikizumab is administered either intravenously (IV) or subcutaneously (SC), depending on the specific study design. Some trials use pre-filled syringes or autoinjectors for SC administration.
  • What are the main goals of the mirikizumab clinical trials? The main goals of the mirikizumab clinical trials are to evaluate its efficacy in inducing and maintaining remission, assess its safety profile, study its pharmacokinetics (how the body processes the drug), and determine its long-term effects in patients with inflammatory bowel diseases.
  • Are there any studies involving pediatric patients? Yes, there are clinical trials specifically designed to study mirikizumab in pediatric patients with ulcerative colitis and Crohn's disease. These studies aim to determine appropriate dosing, efficacy, and safety in children and adolescents.

Ongoing Clinical Trials on Mirikizumab

  • Study of mirikizumab and tirzepatide in adults with moderate to severe ulcerative colitis who are overweight or obese

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • A study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark Germany Italy Poland Spain

  • A study testing how well mirikizumab works to achieve transmural healing in patients with Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Comparing mirikizumab versus azathioprine with glucocorticoids in newly diagnosed patients with moderate-to-severe ulcerative colitis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

    Recruiting

    2 1
    Investigated drugs:
    Austria Denmark Germany Hungary Italy The Netherlands +3

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated drugs:
    Belgium Croatia Czechia Denmark France Germany +8

  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Italy The Netherlands Norway +3

  • Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia France Germany +8

  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +4

Glossary

  • Ulcerative Colitis: A chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Crohn's Disease: A type of inflammatory bowel disease that can affect any part of the digestive tract, causing inflammation, abdominal pain, and other symptoms.
  • Clinical Remission: A state in which the signs and symptoms of the disease are significantly reduced or absent, often measured by specific clinical scores.
  • Endoscopic Remission: The absence or significant reduction of visible inflammation in the intestines when viewed through an endoscope.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous (SC): A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Bioequivalence: The property of two drug formulations having the same biological effect and availability in the body.
  • Modified Mayo Score (MMS): A scoring system used to assess the severity of ulcerative colitis, considering factors such as stool frequency, rectal bleeding, and endoscopic findings.
  • Pediatric Crohn's Disease Activity Index (PCDAI): A tool used to measure the severity of Crohn's disease in children, considering various symptoms and laboratory findings.

References